{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:13Z","timestamp":1792787833594,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Direcci\u00f3n General de Reindustrializaci\u00f3n, Innovaci\u00f3n e Internacionalizaci\u00f3n de la Consejer\u00eda de Desarrollo Auton\u00f3mico del Gobierno de La Rioja","award":["00860-2021\/089142"],"award-info":[{"award-number":["00860-2021\/089142"]}],"id":[{"id":"https:\/\/ror.org\/05cjrnv40","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia de Desarrollo Econ\u00f3mico de La Rioja","award":["2018-I-IDD-00059"],"award-info":[{"award-number":["2018-I-IDD-00059"]}],"id":[{"id":"https:\/\/ror.org\/00k53p435","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia de Desarrollo Econ\u00f3mico de La Rioja","award":["2018-I-IDD-00059"],"award-info":[{"award-number":["2018-I-IDD-00059"]}],"id":[{"id":"https:\/\/ror.org\/00k53p435","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia de Desarrollo Econ\u00f3mico de La Rioja","award":["2018-I-IDD-00059"],"award-info":[{"award-number":["2018-I-IDD-00059"]}],"id":[{"id":"https:\/\/ror.org\/00k53p435","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia de Desarrollo Econ\u00f3mico de La Rioja","award":["2018-I-IDD-00059"],"award-info":[{"award-number":["2018-I-IDD-00059"]}],"id":[{"id":"https:\/\/ror.org\/00k53p435","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Spanish Ministry of Science and Innovation","award":["PID2022-136735OB-I00"],"award-info":[{"award-number":["PID2022-136735OB-I00"]}]},{"name":"Fondo Europeo de Desarrollo Regional","award":["FEDER 2021-2027 N\u00ba 002"],"award-info":[{"award-number":["FEDER 2021-2027 N\u00ba 002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, usually diagnosed at late stages, at which point the best option is palliative chemotherapy. Several treatment sequences are currently used in the clinic, but the optimal sequence is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospectively, 168 PDAC patients treated at a Spanish hospital (single-center study) with either FOLFIRINOX, Gemcitabine (GEM) or Gemcitabine plus nab-paclitaxel (GEM-NABP) as first-line of chemotherapy were studied. Of them, 80 patients received second-line treatment with either GEM- or 5FU-based drugs. Survival analysis was calculated by Kaplan-Meier curves, log-rank test and hazards ratios by univariate and multivariate Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GEM-NABP and FOLFIRINOX presented similar survival outcomes for first-line treatment, and both were better than GEM alone, although FOLFIRINOX presented higher toxicity than GEM-NABP. However, the best second-line option was application of GEM-based drugs after FOLFIRINOX first-line, which offered a better survival and lower toxicity than 5FU-based treatments after GEM-NABP. Specifically, within the most frequent second-line therapies in our cohort, GEM-NABP outperformed FOLFOX6. Thus, individuals that received FOLFIRINOX followed by GEM-NABP treatment presented better outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients deemed eligible for multiple lines of chemotherapy, initiating treatment with FOLFIRINOX followed by a GEM-NABP regimen may represent a beneficial therapeutic sequence for metastatic PDAC, as opposed to the alternative approach of starting with GEM-NABP followed by a 5FU-based regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16391-7","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:07:58Z","timestamp":1782796078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimized chemotherapy sequence for metastatic pancreatic ductal adenocarcinoma patients: FOLFIRINOX followed by Gemcitabine plus nab-paclitaxel"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-7856","authenticated-orcid":false,"given":"Roc\u00edo","family":"del Campo-Pedrosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-2875","authenticated-orcid":false,"given":"Alfonso","family":"Mart\u00edn-Carnicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4684-659X","authenticated-orcid":false,"given":"Ana","family":"Gonz\u00e1lez-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-4044","authenticated-orcid":false,"given":"Alfredo","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"16391_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"16391_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"16391_CR3","unstructured":"SEOM - Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica. Las Cifras del C\u00e1ncer en Espa\u00f1a 2023. 2023. Available from: https:\/\/seom.org\/images\/Las_cifras_del_Cancer_en_Espana_2023.pdf. Cited 2023 Jul 4."},{"key":"16391_CR4","unstructured":"National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Cited 2023 Jul 4."},{"issue":"9","key":"16391_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/MPA.0000000000001662","volume":"49","author":"KE Kaczor-Urbanowicz","year":"2020","unstructured":"Kaczor-Urbanowicz KE, Cheng J, King JC, Sedarat A, Pandol SJ, Farrell JJ, et al. Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers. Pancreas. 2020;49(9):1141\u201352.","journal-title":"Pancreas"},{"issue":"9","key":"16391_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: A Review. JAMA - J Am Med Association. 2021;326(9):851\u201362.","journal-title":"JAMA - J Am Med Association"},{"issue":"1","key":"16391_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12957-023-02896-z","volume":"21","author":"L Yang","year":"2023","unstructured":"Yang L, Su J, Wang W, Zhou F. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study. World J Surg Oncol. 2023;21(1):19.","journal-title":"World J Surg Oncol"},{"key":"16391_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2022.06.042","volume":"174","author":"J Santucci","year":"2022","unstructured":"Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, et al. Impact of first-line FOLFIRINOX versus Gemcitabine\/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Eur J Cancer. 2022;174:102\u201312.","journal-title":"Eur J Cancer"},{"key":"16391_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2023","unstructured":"Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135\u201344.","journal-title":"Eur J Cancer"},{"issue":"16suppl","key":"16391_CR10","doi-asserted-by":"publisher","first-page":"e16262","DOI":"10.1200\/JCO.2023.41.16_suppl.e16262","volume":"41","author":"F Nichetti","year":"2023","unstructured":"Nichetti F, Rota S, Gusmaroli E, Pircher CC, Franza A, De Braud FG, et al. NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials. J Clin Oncol. 2023;41(16suppl):e16262.","journal-title":"J Clin Oncol"},{"key":"16391_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/CMAR.S126073","volume":"9","author":"F Braiteh","year":"2017","unstructured":"Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res. 2017;9:141\u20138.","journal-title":"Cancer Manag Res"},{"issue":"9","key":"16391_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.5306\/wjco.v12.i9.787","volume":"12","author":"H Blomstrand","year":"2021","unstructured":"Blomstrand H, Batra A, Cheung WY, Elander NO. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World J Clin Oncol. 2021;12(9):787\u201399.","journal-title":"World J Clin Oncol"},{"key":"16391_CR13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3748\/wjg.v27.i17.1847","volume":"27","author":"S Cherri","year":"2021","unstructured":"Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol. 2021;27:1847\u201363.","journal-title":"World J Gastroenterol"},{"issue":"23","key":"16391_CR14","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 Trial. J Clin Oncol. 2014;32(23):2423\u20139.","journal-title":"J Clin Oncol"},{"key":"16391_CR15","doi-asserted-by":"publisher","first-page":"10271","DOI":"10.2147\/CMAR.S267393","volume":"12","author":"M Catalano","year":"2020","unstructured":"Catalano M, Conca R, Petrioli R, Ramello M, Roviello G. Folfox vs folfiri as second-line of therapy after progression to gemcitabine\/nab-paclitaxel in patients with metastatic pancreatic cancer. Cancer Manag Res. 2020;12:10271\u20138.","journal-title":"Cancer Manag Res"},{"issue":"8","key":"16391_CR16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/03007995.2022.2059976","volume":"38","author":"G Kim","year":"2022","unstructured":"Kim G, Cockrum P, Surinach A, Wang S, Wainberg Z. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Curr Med Res Opin. 2022;38(8):1295\u2013303.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"16391_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12876-023-02853-w","volume":"23","author":"F Petrelli","year":"2023","unstructured":"Petrelli F, Parisi A, Tomasello G, Mini E, Arru M, Russo A, et al. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. BMC Gastroenterol. 2023;23(1):212.","journal-title":"BMC Gastroenterol"},{"key":"16391_CR18","unstructured":"U.S. Department of Health and Human Services NI of HNCI. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Cited 2024 Apr 18."},{"key":"16391_CR19","doi-asserted-by":"crossref","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E, Ford R, Gwyther S, Mandrekar S et al. RECIST 1.1 - Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"16391_CR20","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from: https:\/\/www.R-project.org\/. Cited 2023 Aug 30."},{"key":"16391_CR21","doi-asserted-by":"crossref","unstructured":"Zhang B, Zhou F, Hong J, Ng DM, Yang T, Zhou X, et al. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. Volume 19. World Journal of Surgical Oncology; 2021.","DOI":"10.1186\/s12957-021-02291-6"},{"key":"16391_CR22","doi-asserted-by":"crossref","unstructured":"Lee YS, Lee Jchan, Kim JH, Kim J, Hwang JH. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Sci Rep. 2021;11(1).","DOI":"10.1038\/s41598-021-99647-5"},{"issue":"4","key":"16391_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/cancers11040484","volume":"11","author":"S Pusceddu","year":"2019","unstructured":"Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and folfirinox in the first-line setting of metastatic pancreatic cancer: A systematic review and meta-analysis. Cancers (Basel). 2019;11(4):484.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"16391_CR24","doi-asserted-by":"publisher","first-page":"16997","DOI":"10.1002\/cam4.6334","volume":"12","author":"K Schlick","year":"2023","unstructured":"Schlick K, Gantschnigg A, Seymer A, Huemer F, Greil R, Weiss L. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. Cancer Med. 2023;12(16):16997\u20137004.","journal-title":"Cancer Med"},{"issue":"4","key":"16391_CR25","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/cam4.4512","volume":"11","author":"S Tezuka","year":"2022","unstructured":"Tezuka S, Ueno M, Oishi R, Nagashima S, Sano Y, Kawano K, et al. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI\/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis. Cancer Med. 2022;11(4):1088\u201398.","journal-title":"Cancer Med"},{"issue":"1","key":"16391_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12885-020-07110-x","volume":"20","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Feeney K, Lee MA, Mu\u00f1oz A, Graci\u00e1n AC, Lonardi S, et al. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer. 2020;20(1):633.","journal-title":"BMC Cancer"},{"issue":"32","key":"16391_CR27","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: A randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16391_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12885-023-11377-1","volume":"23","author":"J Taieb","year":"2023","unstructured":"Taieb J, Seufferlein T, Reni M, Palmer DH, Bridgewater JA, Cubillo A, et al. Treatment sequences and prognostic\/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe. BMC Cancer. 2023;23(1):877.","journal-title":"BMC Cancer"},{"issue":"4","key":"16391_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s12029-018-0166-4","volume":"50","author":"DM Girardi","year":"2019","unstructured":"Girardi DM, Faria LDBB, Teixeira MC, Costa FP, Hoff PMG, Fernandes GS. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? J Gastrointest Cancer. 2019;50(4):860\u20136.","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"16391_CR30","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.21873\/anticanres.16919","volume":"44","author":"M Nishioka","year":"2024","unstructured":"Nishioka M, Okano N, Wakabayashi M, Ikeno T, Hayashi M, Mizutani T, et al. A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy. Anticancer Res. 2024;44(3):1233\u20139.","journal-title":"Anticancer Res"},{"issue":"6","key":"16391_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.dld.2017.02.007","volume":"49","author":"J Viaud","year":"2017","unstructured":"Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bod\u00e8re A, et al. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Dig Liver Disease. 2017;49(6):692\u20136.","journal-title":"Dig Liver Disease"},{"issue":"3","key":"16391_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.pan.2024.02.004","volume":"24","author":"H Yoon","year":"2024","unstructured":"Yoon H, Shin Y, Ryoo BY, Jeong H, Park I, Seo DW, et al. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma. Pancreatology. 2024;24(3):424\u201330.","journal-title":"Pancreatology"},{"issue":"4","key":"16391_CR33","first-page":"550","volume":"14","author":"S Temraz","year":"2023","unstructured":"Temraz S, Kreidieh F, Nassar F, Mezher M, Mukherji D, Shamseddine A. Second-line Modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) Following First-Line FOLFIRINOX in Advanced Pancreatic Cancer: A Retrospective Analysis at the American University of Beirut Medical Center (AUBMC). Middle East J Cancer. 2023;14(4):550\u20138.","journal-title":"Middle East J Cancer"},{"issue":"3","key":"16391_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000521258","volume":"45","author":"A Queck","year":"2022","unstructured":"Queck A, Elango S, Koch C, Walter D, Schmidt J, Trebicka J, et al. Sequence Therapy with FOLFIRINOX and Gemcitabine\/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study. Oncol Res Treat. 2022;45(3):79\u201387.","journal-title":"Oncol Res Treat"},{"issue":"4","key":"16391_CR35","doi-asserted-by":"publisher","first-page":"300060522109322","DOI":"10.1177\/03000605221093225","volume":"50","author":"W Lu","year":"2022","unstructured":"Lu W, Wang L, Li X, Tang K. Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis. J Int Med Res. 2022;50(4):3000605221093225.","journal-title":"J Int Med Res"},{"key":"16391_CR36","doi-asserted-by":"publisher","first-page":"175883592094797","DOI":"10.1177\/1758835920947970","volume":"12","author":"F Foschini","year":"2020","unstructured":"Foschini F, Napolitano F, Servetto A, Marciano R, Mozzillo E, Carrat\u00f9 AC, et al. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Ther Adv Med Oncol. 2020;12:1758835920947970.","journal-title":"Ther Adv Med Oncol"},{"key":"16391_CR37","doi-asserted-by":"crossref","unstructured":"Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S et al. Multicenter retrospective analysis of second-line therapy after gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients. Cancers (Basel). 2020;12(5).","DOI":"10.3390\/cancers12051131"},{"key":"16391_CR38","doi-asserted-by":"crossref","unstructured":"Park HS, Kang B, Chon HJ, Im HS, Lee CK, Kim I et al. Liposomal irinotecan plus fluorouracil\/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open. 2021;6(2).","DOI":"10.1016\/j.esmoop.2021.100049"},{"key":"16391_CR39","doi-asserted-by":"crossref","unstructured":"Leroux C, Konstantinidou G. Targeted therapies for pancreatic cancer: Overview of current treatments and new opportunities for personalized oncology. Cancers. 2021;13, p. 799.","DOI":"10.3390\/cancers13040799"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16391-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:17:20Z","timestamp":1789694240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16391-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16391"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16391-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Medical Research Ethics Committee of La Rioja (CEICLAR, protocol number 260) on August 24th, 2017.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1114"}}